Thursday, January 20, 2022

Natco Pharma

Natco Pharma net dips 68% in Q2

Hyderabad: Hyderabad-based Natco Pharma reported a dip in its net profit for the quarter ended September 30, 2021 to Rs 65.1 crore as against...

Very soon, a pill to treat Covid-19

Hyderabad: A simple pill to treat Covid-19 positive patients! Yes, an anti-viral pill that could be easily prescribed and taken orally by Covid positive...

Natco Pharma net dips 43% in Q4

For the entire 2020-21 fiscal, the company posted a consolidated net profit of Rs 442 crore as compared with Rs 458 crore in 2019-20.

Hyderabad: Phase III trials of Molnupiravir begin at Yashoda Hospitals

Natco Pharma had recently received approval from the Drug Controller General of India (DCGI) to conduct phase III clinical trials of Molnupiravir

Exploring all options to procure enough vaccines: KTR

Task Force also discussed with them various alternatives to drugs that are in high demand like Remdesivir

Natco Pharma board okays acquiring 1% in Canadian arm

Stocks of Natco Pharma were trading 0.74 per cent lower at Rs 810.85 apiece on BSE. 

Cancer Clinics raises pre-Series A funding from Axilor, others

Hyderabad-headquartered comprehensive cancer care provider expects to close Series A funding in the second half of 2021

Natco Pharma forays into pheromone-based technology for integrated pest management

With this launch, cotton farmers will have a new and powerful tool to manage PBW, Natco Pharma said.

Natco Pharma Q3 net profit declines 39 pc to Rs 63 cr

The consolidated total income of the company stood at Rs 386 crore for the quarter under consideration.

Natco Pharma eyes launch of 8-10 new drugs yearly

During the year, Natco spent Rs 349 crore on capital expenditure, a majority of which was used to enhance capabilities of their manufacturing facilities

Latest News

- Advertisement -